Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
Marina Talamonti,1 Filomena Russo,2 Giovanna Malara,3,4 Katharina Hansel,5 Manuela Papini,6 Angelo Cattaneo,7 Aurora Parodi,8 Andrea Chiricozzi,9,10 Piergiorgio Malagoli,11 Federico Bardazzi,12 Valeria Brazzelli,13 Paolo Dapavo,14 Paolo Gisondi,15 Cristina Zane,16 Concetta Potenza,17 Franca Cantores...
Main Authors: | Talamonti M, Russo F, Malara G, Hansel K, Papini M, Cattaneo A, Parodi A, Chiricozzi A, Malagoli P, Bardazzi F, Brazzelli V, Dapavo P, Gisondi P, Zane C, Potenza C, Cantoresi F, Fargnoli MC, Trevisini S, Brianti P, Pescitelli L, Gigante G, Bartezaghi M, Caputo L, Aloisi E, Costanzo A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-04-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Subjects: | |
Online Access: | https://www.dovepress.com/efficacy-and-safety-of-secukinumab-in-elderly-patients-with-moderate-t-peer-reviewed-fulltext-article-CCID |
Similar Items
-
Secukinumab in multi-failure psoriatic patients: the last hope?
by: M. Magnano, et al.
Published: (2018-08-01) -
Secukinumab for the treatment of residual psoriasis: a case series
by: Piergiorgio Malagoli
Published: (2018-11-01) -
Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
by: Russo F, et al.
Published: (2023-12-01) -
Secukinumab
by: Nilgün Atakan
Published: (2022-04-01) -
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
by: Paolo Gisondi, et al.
Published: (2022-04-01)